Extendicare (TSE:EXE – Get Free Report) was upgraded by Royal Bank Of Canada from a “sector perform” rating to an “outperform” rating in a note issued to investors on Thursday,BayStreet.CA reports. The brokerage currently has a C$25.00 target price on the stock, up from their prior target price of C$15.00. Royal Bank Of Canada’s price objective points to a potential upside of 12.06% from the stock’s previous close.
EXE has been the topic of several other research reports. National Bankshares raised their target price on Extendicare from C$21.50 to C$24.50 and gave the stock an “outperform” rating in a research report on Wednesday. Natl Bk Canada upgraded shares of Extendicare to a “strong-buy” rating in a research note on Wednesday. TD Securities boosted their price objective on shares of Extendicare from C$15.00 to C$19.00 in a research report on Thursday, November 13th. Cormark upped their target price on shares of Extendicare from C$25.00 to C$30.00 in a report on Wednesday. Finally, CIBC lifted their price target on Extendicare from C$18.00 to C$22.00 in a research report on Thursday, November 13th. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of C$23.86.
Read Our Latest Stock Report on Extendicare
Extendicare Stock Up 6.3%
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- How to Buy Gold Stock and Invest in Gold
- The Nuclear Revival Is Real: SMR Stocks Flash Buy Signals After DOE Push
- What is a Stock Market Index and How Do You Use Them?
- Boeing’s Bullish Breakout: Is This Rally Cleared for Takeoff?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Wolfspeed Just Got a $698 Million Lifeline—Here’s Why That Changes Everything
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
